The latest news from the global pharmaceutical industry. Below you will find news and information to keep you up-to-date with what is happening in your industry. Coverage includes regulatory approvals, recall announcements, mergers and acquisitions, personnel news and appointments, new facility and facility expansion updates, collaborations and agreements, and financial updates.
Intec Pharma announced that the last patient has completed their final visit in the Company's trial evaluating the safety and efficacy of the ...
read more
3-V Biosciences and Ascletis Pharma announced 3-V Biosciences has recently dosed its first patient in a Phase 2 clinical trial of the FASN inhibitor ...
read more
AKLRD and Nordic Bioscience Clinical Development, announced a risk-share agreement to assess the efficacy of a novel, oral medicine, APPA, in a phase ...
read more
Inovio announced its lead Phase 3 product candidate, VGX-3100, has been granted an Advanced Therapy Medicinal Product Certificate for quality and non-...
read more
AstraZeneca Pharmaceuticals
Daiichi Sankyo and AstraZeneca today announced positive topline results for the pivotal phase 2 DESTINY-Breast01 trial of [fam-] trastuzumab ...
read more
Provention Bio announced preliminary top-line results from its Phase 1b PULSE study which evaluated PRV-300, an anti-TLR3 monoclonal antibody, in ...
read more
The FDA plays an important role in helping to address the high cost of medicines through the development of generic drugs, biosimilars, and ...
read more
Wellspring Biosciences announced the FDA has cleared an IND application for ARS-3248, a small molecule KRAS G12C inhibitor.
read more
The MDA announced the awarding of 26 new grants totaling more than $7.5 million toward research focused on a variety of rare neuromuscular diseases (...
read more
Wellspring Biosciences announced the FDA has cleared an IND application for ARS-3248, a small molecule KRAS G12C inhibitor.
read more
Inovio, together with CEPI, has dosed subjects in a Phase 1, first-in-human clinical trial to evaluate INO-4500, its DNA candidate vaccine to prevent ...
read more
89bio LTD announced positive top-line results from a Phase 1 single ascending dose (SAD) study of its investigational medicine, BIO89-100, in healthy ...
read more
OncoSec has announced interim data from an ongoing Phase 2 study of TAVO™ in combination with KEYTRUDA® in patients with refractory triple negative ...
read more
Immunovant has initiated dosing in ASCEND-GO 1, an open label, single-arm Phase 2a clinical trial evaluating IMVT-1401 in patients with moderate-to-...
read more
Ethicann Pharmaceuticals announced a development and commercial supply partnership with Ilera Therapeutics.
read more